ImpriMed CEO Dr. Sungwon Lim Invited to National Cancer Institute Panel on Commercializing Functional Precision MedicineImpriMed, a leading functional precision medicine company focused on leveraging artificial intelligence to improve cancer treatment, today announced that its CEO and Co-Founder, Dr. Sungwon Lim, has been invited by the National Cancer Institute (NCI) to serve as a panelist at Precision in Practice: A Functional Medicine Workshop. The hybrid workshop takes place July 1 and 2, 2026, in person at the NCI Shady Grove Campus in Rockville, Maryland, and online.
